SUMMARY Doppler ultrasound measurements of pulmonary blood flow in 20 babies with severe respiratory distress syndrome treated in a randomised controlled trial of surfactant replacement showed that the immediate improvement of oxygenation was not associated with a significant increase in pulmonary blood flow. Reduction in ventilator settings and increases in the extent of chest wall movements measured by a cardiorespiratory monitor suggested that the improvement after surfactant had been given was a result of alveolar stabilisation and increased pulmonary compliance. Further simultaneous studies of pulmonary blood flow and pulmonary compliance are needed to confirm these findings.
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Natural surfactant has been used to reverse the effects of respiratory failure in animals. 1-5 These studies showed an almost instantaneous increase in arterial oxygen tension followed by a more gradual change in pH and arterial carbon dioxide tension. This rapid improvement in oxygenation was reminiscent of the action of tolazoline in babies with pulmonary hypertension, and we wondered if surfactant acted like a pulmonary vasodilator drug.
In lambs changes in pulmonary compliance can be detected 15-30 minutes after giving surfactant -3 but pulmonary blood flow either does not change4 or increases after a delay of about two to three hours.5 In immature baboons both compliance and pulmonary blood flow increase after instillation of surfactant, pulmonary blood flow by threefold.6 As far as we are aware there have been no studies of pulmonary blood flow changes in babies after surfactant treatment.
Patients and methods
Based on the threefold increase in pulmonary blood flow in immature baboons after surfactant treatment6 we estimated that to detect a similar change in babies with a power of 80% and a probability of <0-05 (two tailed test) would require a sample of 20 patients.
Serial measurements of pulmonary blood flow were made in 20 consecutive babies who were taking part in a randomised controlled trial of surfactant replacement.7 All babies entering the study had severe respiratory distress syndrome requiring 13 mechanical ventilation with >60% oxygen when less than 15 hours old.7
The surfactant was isolated from porcine lungs by chloroform-methanol extraction and further purified by liquid-gel chromatography8; it was given in a total dose of 200 mg/kg (2.5 ml/kg) 
Results
The 12 treated babies had a mean (SD) birth weight of 1335 (312) g and gestational age 28-4 (1-1) weeks. The median age at enrolment was 5 hours (range 2-13). The eight control infants had a mean birth weight of 1401 (258) g and gestational age 28-8 (1.9) weeks; their median age at enrolment was 7 hours (range 2-15). Fifteen babies were given muscle relaxants during ventilation (eight treated and seven controls).
Fig 1 compares the changes in arterial to alveolar oxygen tension ratio with the calculated measure of mechanical ventilation and pulmonary blood flow in ml/kg/minute. There was an immediate increase in arterial:alveolar oxygen tension ratio so that treated babies had significantly higher ratios from 15 minutes to four hours (fig 1 and table) 
